Autres langues Virios Therapeutics, Inc.

Actions

VIRI

US92829J1043

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 03/05/2024			Varia. 5j.	Varia. 1 janv.
0,4115 ^USD	-2,30%		-12,35%	-28,43%

29/02	Virios Therapeutics, Inc. annonce ses résultats pour le quatrième trimestre et l'exercice clos le 31 décembre 2023	CI
22/01	Virios Therapeutics annonce son intention de faire progresser le développement de l'Imc-2 en tant que traitement des symptômes associés à la maladie de Long-Covid	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024	02/05
Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID	26/03
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results	01/03
Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones	29/02
Virios Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	29/02
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results	29/02
Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones	28/02
Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID	22/01
Virios Therapeutics Announces Plans to Advance Development of Imc-2 as Treatment for Symptoms Associated with Long-Covid	22/01
Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID	02/01
Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID	02/01
Virios Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update	13/11
Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023	06/11
Thinking about buying stock in Aware, Virios Therapeutics, Bit Brother, Confluent, or Blue Star Foods?	03/11
Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023	12/10/23
Virios Therapeutics, Inc. Announces Termination of At-The-Market Sales Agreement	18/09/23
Virios Therapeutics Announces Termination of At-The-Market Sales Agreement	18/09/23
Virios Therapeutics CEO Greg Duncan to Present at the SHARE Series Investor Event on Monday, September 18, 2023	13/09/23
Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023	12/09/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Virios Therapeutics, Inc.

Actions

VIRI

US92829J1043

Autres langues

Filtres